Display options
Cite
Mehdizadeh M, Fereshtehnejad SM, Goudarzi S, et al. Validity and Reliability of Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) in Iranian People with Parkinson's Disease. Parkinsons Dis. 2020;2020:2793945doi: 10.1155/2020/2793945.
Mehdizadeh, M., Fereshtehnejad, S. M., Goudarzi, S., Moshtagh, A., Dehghanian Nasrabadi, F., Habibi, S. A. H., & Taghizadeh, G. (2020). Validity and Reliability of Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) in Iranian People with Parkinson's Disease. Parkinson's disease, 20202793945. https://doi.org/10.1155/2020/2793945
Mehdizadeh, Maryam, et al. "Validity and Reliability of Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) in Iranian People with Parkinson's Disease." Parkinson's disease vol. 2020 (2020): 2793945. doi: https://doi.org/10.1155/2020/2793945
Mehdizadeh M, Fereshtehnejad SM, Goudarzi S, Moshtagh A, Dehghanian Nasrabadi F, Habibi SAH, Taghizadeh G. Validity and Reliability of Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) in Iranian People with Parkinson's Disease. Parkinsons Dis. 2020 Aug 18;2020:2793945. doi: 10.1155/2020/2793945. eCollection 2020. PMID: 32908666; PMCID: PMC7450331.
Copy Download .nbib Format: NLM
Share it on

Parkinsons Dis. 2020 Aug 18;2020:2793945. doi: 10.1155/2020/2793945. eCollection 2020.

Validity and Reliability of Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) in Iranian People with Parkinson's Disease.

Parkinson's disease

Maryam Mehdizadeh, Seyed-Mohammad Fereshtehnejad, Sepide Goudarzi, Ainaz Moshtagh, Farzaneh Dehghanian Nasrabadi, Sayed Amir Hasan Habibi, Ghorban Taghizadeh

Affiliations

  1. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
  2. Department of Neurosciences, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
  3. Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institute, Stockholm, Sweden.
  4. Division of Neurology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  5. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran.
  6. Department of Optometry, Faculty of Rehabilitation Sciences, Shahid Beheshti of Medical Science, Tehran, Iran.
  7. Department of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran.
  8. Rehabilitation Research Center, Department of Occupational Therapy, School of Rehabilitation Sciences, Iran University of Medical Science, Tehran, Iran.

PMID: 32908666 PMCID: PMC7450331 DOI: 10.1155/2020/2793945

Abstract

PURPOSE: Pain is one of the nonmotor symptoms of Parkinson's disease (PD) that, in order to be better managed, requires to be evaluated. Evaluations are done using pain assessment scales such as the Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2). The goal of this study was to assess the psychometric properties of SF-MPQ-2 to measure pain in people with PD.

METHODS: Four hundred and twenty-eight PD patients with a mean (SD) age of 60.11 (11.44) years were included. Accessibility was measured through floor and ceiling effects. Dimensionality was estimated by exploratory factor analysis. The association between SF-MPQ-2 and other scales such as Neuropathic Pain Symptom Inventory, Douleur Neuropathic 4, Brief Pain Inventory, King's Pain Parkinson's Disease Scale, and Visual Analog Scale-Pain was considered to calculate convergent validity. Internal consistency and test-retest reliability were assessed by Cronbach's alpha and intraclass correlation coefficient (ICC), respectively.

RESULTS: A noticeable floor effect was found. Dimensionality results indicated four factors for this scale. A strong relationship was found between the SF-MPQ-2 total score and other scales (

CONCLUSION: The results of this study showed that SF-MPQ-2 has adequate validity and reliability to measure pain in people with Parkinson's disease.

Copyright © 2020 Maryam Mehdizadeh et al.

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

  1. Int J Rheum Dis. 2019 Nov;22(11):2031-2044 - PubMed
  2. Saudi J Anaesth. 2017 May;11(Suppl 1):S80-S89 - PubMed
  3. Neurol Sci. 2009 Apr;30(2):99-106 - PubMed
  4. J Pain. 2015 Apr;16(4):357-66 - PubMed
  5. Arch Bone Jt Surg. 2015 Jan;3(1):45-50 - PubMed
  6. Mov Disord. 2010 Nov 15;25(15):2493-500 - PubMed
  7. Mov Disord. 2012 Apr;27(4):485-91 - PubMed
  8. J Neurol. 2013 Jan;260(1):330-4 - PubMed
  9. Parkinsonism Relat Disord. 2004 Mar;10(3):129-36 - PubMed
  10. Mov Disord. 2005 Dec;20(12):1557-63 - PubMed
  11. Phys Ther. 2001 Feb;81(2):810-8 - PubMed
  12. Arch Phys Med Rehabil. 2012 Jan;93(1):163-6 - PubMed
  13. Parkinsonism Relat Disord. 2013 May;19(5):548-52 - PubMed
  14. Pain Med. 2012 Dec;13(12):1631-6 - PubMed
  15. Pain Pract. 2014 Jun;14(5):427-36 - PubMed
  16. Neurologia. 2012 Oct;27(8):500-3 - PubMed
  17. Stroke. 2011 Jun;42(6):1712-6 - PubMed
  18. Pain Res Manag. 2019 Oct 8;2019:5050979 - PubMed
  19. J Pain Res. 2017 Jan 05;10:121-128 - PubMed
  20. J Pain. 2014 Jul;15(7):756-70 - PubMed
  21. J Pain Symptom Manage. 2017 Jul;54(1):132-138.e2 - PubMed
  22. Pain. 2004 Apr;108(3):248-57 - PubMed
  23. Spine (Phila Pa 1976). 2019 Jul 1;44(13):E774-E781 - PubMed
  24. Mov Disord Clin Pract. 2016 Jun 24;3(6):527-537 - PubMed
  25. Mov Disord. 2015 Oct;30(12):1623-31 - PubMed
  26. Neurology. 2008 Apr 29;70(18):1630-5 - PubMed
  27. J Pers Assess. 1997 Jun;68(3):532-60 - PubMed
  28. Health Qual Life Outcomes. 2014 May 20;12:78 - PubMed
  29. Pain. 2009 Jul;144(1-2):35-42 - PubMed
  30. Pain. 2009 Jan;141(1-2):173-7 - PubMed
  31. Neurodegener Dis. 2010;7(5):284-90 - PubMed
  32. Curr Neurol Neurosci Rep. 2016 Apr;16(4):28 - PubMed

Publication Types